Form 8-K - Current report:
SEC Accession No. 0001326190-24-000053
Filing Date
2024-12-11
Accepted
2024-12-11 17:19:34
Documents
14
Period of Report
2024-11-15
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K alt-20241115x8k.htm   iXBRL 8-K 38642
  Complete submission text file 0001326190-24-000053.txt   177936

Data Files

Seq Description Document Type Size
2 EX-101.SCH alt-20241115.xsd EX-101.SCH 3271
3 EX-101.LAB alt-20241115_lab.xml EX-101.LAB 18716
4 EX-101.PRE alt-20241115_pre.xml EX-101.PRE 12849
16 EXTRACTED XBRL INSTANCE DOCUMENT alt-20241115x8k_htm.xml XML 4916
Mailing Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878
Business Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878 2406541450
Altimmune, Inc. (Filer) CIK: 0001326190 (see all company filings)

EIN.: 202726770 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32587 | Film No.: 241542431
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)